Articles
16 June 2009
Vol. 2 No. 15: Secondary Leukemias and leukemogenesis Rome, 3-4 November 2006
https://doi.org/10.4081/hmr.v2i15.604

Detoxification enzyme polymorphisms as risk factors fo t-AML

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
258
Views
309
Downloads

Authors

Maria Teresa Voso
support@pagepress.org
Francesco D’Alò
Giuseppe Leone
Todate, therapy-related myelodysplastic syndromes/acute Myeloid Leukemias (t-MDS/ AML) represent the main long-term adverse effect of cancer treatment. The identification of new prognostic factors has raised the question whether reducing treatment intensity in good prognosis patients may save them from long term-toxicity, without impairing response rates.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Detoxification enzyme polymorphisms as risk factors fo t-AML. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(15). https://doi.org/10.4081/hmr.v2i15.604